Enveric Biosciences, Inc. (ENVB): Nasdaq/NYSE listing notice — Enveric Biosciences announces 1-for-12 reverse stock split to address Nasdaq bid-price deficiency

Enveric Biosciences, Inc.

Reverse split effective 8:00 a.m. ET on October 28, 2025; shares outstanding to drop from 6,219,568 to ~518,297.
Nasdaq notified company on Oct 22 of bid-price non-compliance (closing price <$1 for 30 days); no grace period due to prior reverse split.
Company received $2.2M gross from warrant exercises in September to raise stockholders' equity above $2.5M minimum.
Company intends to request a hearing to appeal delisting; no assurance of continued listing.
Warrants issued in the inducement become exercisable only after stockholder approval per Nasdaq Rule 5635(d).

item 3.01 item 3.03 item 5.03 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Enveric Biosciences, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

the “Company”) received a notice from The Nasdaq Stock Market (the “Nasdaq”) indicating that it no longer met the continued listing requirements. Specifically, the Company’s stockholders’ equity was below the minimum required stockholders’ equity of $2.5 million as stipulated by Nasdaq Listing Rule 5550(b)(1) (“Rule 5550(b)(1)”). As noted in the Original 8-K, the Company had until October 10, 2025 to provide Nasdaq with a specific plan to achieve and sustain compliance. The Company submitted its plan to regain compliance on October 10, 2025. The Company is filing this Current Report on Form 8-

View on SEC.gov

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Enveric Biosciences, Inc.: Certificate of Amendment filed to effect 1-for-12 reverse stock split of common stock (effective 2025-10-28).

Change: charter amendment
Effective: 2025-10-28

Exact text from the filing

On October 23, 2025, the Company filed a Certificate of Amendment of Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of Delaware to effect a 1-for-12 reverse stock split of the shares of the Company’s Common Stock, either issued and outstanding or held by the Company as treasury stock, effective as of 8:00 a.m. (New York time) on October 28, 2025 (the “Reverse Stock Split”).

View on SEC.gov

Browse all listing & compliance notices →

Enveric Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-25-019095

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.